flurbiprofen has been researched along with fluconazole in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Duffy, EM; Jorgensen, WL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Basu, P; Elias, R; Fridman, M | 1 |
| Greenblatt, DJ; Harmatz, JS; Luo, Y; Perloff, ES; von Moltke, LL; Zinny, MA | 1 |
| Branch, RA; Frye, RF; Romkes, M; Tracy, TS; Zgheib, NK | 1 |
| Brundage, RC; Kumar, V; Leppik, IE; Oetting, WS; Tracy, TS | 1 |
| Chabert, J; Daali, Y; Dayer, P; Déglon, J; Desmeules, J; Rebsamen, M; Samer, C; Staub, C; Thomas, A | 1 |
| Cancalon, PF; Court, MH; Dolnikowski, GG; Greenblatt, DJ; Hanley, MJ; Harmatz, JS; Masse, G | 1 |
| Court, MH; Greenblatt, DJ; Hanley, MJ; Harmatz, JS; Masse, G | 1 |
2 review(s) available for flurbiprofen and fluconazole
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for flurbiprofen and fluconazole
| Article | Year |
|---|---|
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies.
Topics: Adult; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Area Under Curve; Beverages; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Fluconazole; Flurbiprofen; Food-Drug Interactions; Half-Life; Humans; In Vitro Techniques; Male; Microsomes, Liver; Tea; Vaccinium macrocarpon; Vitis | 2006 |
Differential genotype dependent inhibition of CYP2C9 in humans.
Topics: Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C9; Enzyme Inhibitors; Fluconazole; Flurbiprofen; Genotype; Humans; Reference Values | 2008 |
Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers.
Topics: Adult; Anthocyanins; Aryl Hydrocarbon Hydroxylases; Beverages; Blueberry Plants; Buspirone; Citrus paradisi; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Fluconazole; Flurbiprofen; Food-Drug Interactions; Furocoumarins; Humans; Male; Microsomes, Liver; Middle Aged; Phenols | 2013 |
Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Beverages; Cytochrome P-450 CYP2C9; Female; Fluconazole; Flurbiprofen; Food-Drug Interactions; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lythraceae; Male; Middle Aged; Plant Extracts; Young Adult | 2012 |
12 other study(ies) available for flurbiprofen and fluconazole
| Article | Year |
|---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Fluconazole-COX Inhibitor Hybrids: A Dual-Acting Class of Antifungal Azoles.
Topics: Antifungal Agents; Candida; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P450 Family 51; Ergosterol; Fluconazole; Microbial Sensitivity Tests; Stereoisomerism | 2022 |
Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.
Topics: Administration, Oral; Adult; Antifungal Agents; Biomarkers; Cytochrome P-450 Enzyme System; Female; Fluconazole; Flurbiprofen; Genotype; Humans; Male; Phenotype | 2007 |
Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Dried Blood Spot Testing; Fluconazole; Flurbiprofen; Genotype; Humans; Hydrolysis; Male; Rifampin; Young Adult | 2012 |